According to the World Health Organization, air pollution kills millions of people every year. In fact, carbon dioxide exacerbates respiratory conditions in patients suffering from COPD and Asthma – often leading these patients to premature deaths.
AstraZeneca Brazil created an innovative way to bring awareness to this epidemic. This past March, they launched the CO2 Inhaler, marking the first time pollution has been used to help patients breathe better. This special edition inhaler is made from carbon dioxide converted into biodegradable plastic, in order to create the plastic device which houses the canister of medication.
“AstraZeneca is committed to become carbon negative by 2030. The CO2 Inhaler sets a precedent for the future where it can tackle two issues at once. The health of our patients, and the health of our environment,” said AstraZeneca Brazil’s Senior Product Manager, Viviane Milício.
The CO2 Inhaler is a collaboration between AstraZeneca Brazil, and the combined offices of McCann Health Sao Paulo and New York.
Together, they worked with one of the world’s top 100 chemists – Cornell University’s, Geoffrey Coates, who has been leading research and development of CO2 converted into plastic for over a decade. In addition, the team worked with Novomer, a leading sustainable manufacturing company Coates co-founded that specializes in the polymerization of carbon dioxide.
Watch the case film below:
For more information about the inhaler, and AstraZeneca’s pledge to become Carbon Negative by 2030, please visit the site: